Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | APAF1 | O14727 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.37 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.36 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.36 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.36 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16884603 | 1.00 | HTR6 (0.42) | HTR6APAF1MAPTKDM4EPOLB | |
| SCHEMBL20362355 | 0.81 | SLC7A5 (0.50) | HTR6MAPTKDM4EKMT2A | |
| SCHEMBL13607877 | 0.81 | SLC7A5 (0.50) | HTR6MAPTKDM4EKMT2A | |
| SCHEMBL5320574 | 0.81 | SLC7A5 (0.50) | HTR6MAPTKDM4EKMT2A | |
| SCHEMBL26552691 | 0.78 | HTR6 (0.42) | HTR6L3MBTL1 | |
| SCHEMBL25453849 | 0.78 | HTR6 (0.44) | HTR6KMT2A | |
| SCHEMBL20996644 | 0.78 | HTR6 (0.44) | HTR6 | |
| SCHEMBL30307384 | 0.78 | HTR6 (0.44) | HTR6 | |
| SCHEMBL20202512 | 0.77 | PTPN1 (0.38) | HTR6MAPTALOX15SMN1; SMN2PTPN1 | |
| SCHEMBL22927954 | 0.77 | HTR6 (0.44) | HTR6KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180022786-A1 | NOVEL SODIUM CHANNEL BLOCKING PEPTIDES AND THE USE THEREOF | PURDUE PHARMA L.P. | 2018-01-25 | — | — | US | disclosed |
| US-9718865-B2 | Sodium channel blocking peptides and the use thereof | PURDUE PHARMA L.P. (US) | 2017-08-01 | — | — | US | disclosed |
| US-20150191517-A1 | NOVEL SODIUM CHANNEL BLOCKING PEPTIDES AND THE USE THEREOF | PURDUE PHARMA L.P. (US) | 2015-07-09 | — | — | US | disclosed |
| US-8466291-B2 | 1,5-dideoxy-1,5-imino-D-glucitol compounds | ACADEMIA SINICA (TW) | 2013-06-18 | — | — | US | disclosed |
| US-7662999-B2 | Recognition of oligosaccharide molecular targets by polycationic small molecule inhibitors and treatment of immunological disorders and infectious diseases | NATIONAL INSTITUTES OF HEALTH (NIH) (US) | 2010-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180022786-A1 | NOVEL SODIUM CHANNEL BLOCKING PEPTIDES AND THE USE THEREOF | SCN7A, SCN2B, SCN2A | HTR6 2962/4885APAF1 2257/4885MAPT 3984/4885 |
| US-20150191517-A1 | NOVEL SODIUM CHANNEL BLOCKING PEPTIDES AND THE USE THEREOF | SCN7A, SCN2A, SCN5A | HTR6 2861/4885APAF1 1456/4885MAPT 4023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.